BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Deals

  265 Employees Affected as San Diego’s Dart NeuroScience Decides to Close Its Doors

  Dart will close its doors on Feb. 9 due to poor progress on its therapeutic goals and little return on hundreds of millions of dollars in R&D.

  December 12, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Sanofi Investors Crave for a Large Acquisition, Drug News

  As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting antsy for some good news.

  December 12, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Bay Area’s Aduro Biotech Throws in the Towel on CRS-207, Will Wind Down Trials

  The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies.

  December 12, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Genetown

  Why This Massachusetts Synthetic Bio Startup Could be the Next Biotech Unicorn

  In investment jargon, a “unicorn” has at least two meanings.

  December 12, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Should Teva Start Cutting at the Bottom or the Top?

  These are tough times for Teva.

  December 12, 2017

   · 

  1 min read
• 

  Deals

  Denali Raises a Mountain of Cash

  A look at what three ex-Genentech employees have accomplished at Denali so far.

  December 12, 2017

   · 

  1 min read
• 

  Business

  What You Need to Know About Prelude Fertility

  Prelude Fertility was founded in late 2016 by successful startup entrepreneur Martin Varsavsky with a $200M investment.

  December 12, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Allergan Swoops in and Bags Troubled Repros Therapeutics

  The deal is expected to close in the first quarter of 2018.

  December 12, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie, Genentech’s Venclexta Plus Rituxan Crushes Chemo in Rituxan CLL Study

  At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.

  December 12, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  J&J, Sanofi Top Bioethics International Transparency Report

  Rounding out the top five companies behind J&J and Sanofi are AbbVie, Celgene and Merck.

  December 12, 2017

   · 

  4 min read

   · 

  Alex Keown